BRIEF-Leads Biolabs Announces Partner Oblenio Bio’S $62 Million Oversubscribed Series B Financing To Advance Tri-Specific T-Cell Engager Lbl‑051 For Autoimmune Diseases Into Clinical Development

Pfizer Inc.

Pfizer Inc.

PFE

0.00

June 25 (Reuters) - Nanjing Leads Biolabs Co Ltd 9887.HK:

  • LEADS BIOLABS ANNOUNCES PARTNER OBLENIO BIO’S $62 MILLION OVERSUBSCRIBED SERIES B FINANCING TO ADVANCE TRI-SPECIFIC T-CELL ENGAGER LBL‑051 FOR AUTOIMMUNE DISEASES INTO CLINICAL DEVELOPMENT

  • NANJING LEADS BIOLABS CO - SERIES B ROUND LED BY PFIZER VENTURES WITH DEEP TRACK CAPITAL, GV, AND ADITUM BIO

Source text: ID:nGNX9R9c4R

Further company coverage: 9887.HK


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.